1 results match your criteria: "all at Mount Sinai School of Medicine in New York[Affiliation]"
Direct-acting antiviral agents in patients with hepatitis C cirrhosis.
Gastroenterol Hepatol (N Y)
November 2012
Dr. Im is an Assistant Professor of Medicine in the Division of Liver Diseases, and Dr. Dieterich is a Professor of Medicine in the Division of Liver Diseases, Director of CME in the Department of Medicine, and Director of Outpatient Hepatology, all at Mount Sinai School of Medicine in New York, New York.
Patients with cirrhosis who are infected with hepatitis C virus (HCV) are the most in need of antiviral treatment. Virologic cure improves fibrosis and quality of life while reducing liver-related morbidity and mortality. In mid-2011, the addition of direct-acting antiviral agents (DAAs)-the protease inhibitors boceprevir (Victrelis, Merck) and telaprevir (Incivek, Vertex)-to pegylated interferon α-2a/b and ribavirin revolutionized the treatment of HCV infection by increasing cure rates across all fibrosis scores in patients with genotype 1 HCV infection.
View Article and Find Full Text PDF